Element Biosciences
San Diego, California, United States · Biotechnology, Genetics, Health Care · 390 employees
Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. We are developing a modular and high-performing DNA sequencing platform that will deliver high-quality data, increase workflow flexibility, and make next-generation sequencing technology more accessible. Our proprietary approach to improving the signal-to-noise
Funding history
- Series series e — $175.0M — Jun 2026
- Series series d — $277.0M — Jul 2024
Recent signals
- Jun 09, 2026: Raised $175.0M in Series series e
- Feb 20, 2025: Launched Element Biosciences, Inc. unveils AVITI24™ Innovation Roadmap to enhance research capabilities and accelerate drug development during AGBT 2025.
- Oct 16, 2024: Launched Element Biosciences Launches Trinity™, a Targeted Sequencing Innovation to Simplify Genomic Research.
- Jul 11, 2024: Raised $277.0M in Series series d
- Jun 26, 2024: Element Biosciences Appoints Amirali Kia, PhD as Vice President of Artificial Intelligence and Tina Tian, PhD as Vice President of Portfolio Management
- Mar 12, 2024: Element Biosciences Appoints Danae Van Oene as Senior Vice President of Global Sales and Support
- Aug 24, 2023: Element Biosciences Adds Genomics Executive to Leadership Team to Accelerate Corporate Development
- Jul 13, 2023: Element Biosciences Announces Genomics Industry Veteran as Senior Vice President of Marketing and Product Management
See plans & pricing → Track Element Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.